Related Articles
Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review)
Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)
ALK inhibitors and advanced non-small cell lung cancer (Review)
Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non‑small‑cell lung cancer (Review)